Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 6
1991 13
1992 13
1993 26
1994 35
1995 32
1996 36
1997 83
1998 140
1999 120
2000 118
2001 103
2002 137
2003 125
2004 127
2005 158
2006 174
2007 182
2008 229
2009 238
2010 245
2011 309
2012 360
2013 319
2014 293
2015 249
2016 196
2017 203
2018 173
2019 89
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

3,949 results
Results by year
Filters applied: . Clear all
Page 1
Gadolinium Deposition in the Brain: Current Updates.
Choi JW and Moon WJ. Korean J Radiol 2019 - Review. PMID 30627029 Free PMC article.
Gadolinium-based contrast agents (GBCAs) are commonly used for enhancement in MR imaging and have long been considered safe when administered at recommended doses. ...
Gadolinium-based contrast agents (GBCAs) are commonly used for enhancement in MR imaging and have long been considered safe when admi
REPLY
Hill B, et al. AJNR Am J Neuroradiol 2018. PMID 29700050 Free article.
Gadolinium released by the linear gadolinium-based contrast-agent Gd-DTPA decreases the activity of human epithelial Na(+) channels (ENaCs).
Knoepp F, et al. Biochim Biophys Acta Biomembr 2017. PMID 28257815 Free article.
BACKGROUND: Gadolinium-based-contrast-agents (GBCAs) are used for magnetic-resonance-imaging and associated with renal and cardiovascular adverse reactions caused by released Gd(3+) ions. ...Linear Gd-DTPA and Magnevist mimicked the effect of ≤0.3mmol/l Gd(3+), whereas the chelator DTPA showed no effect. Gd(3+) and Gd-DTPA increased the IC(50) for amiloride, but did not affect ENaC's self-inhibition. ...
BACKGROUND: Gadolinium-based-contrast-agents (GBCAs) are used for magnetic-resonance-imaging and associated with renal and cardiovasc …
Hydrodenticity to enhance relaxivity of gadolinium-DTPA within crosslinked hyaluronic acid nanoparticles.
Russo M, et al. Nanomedicine (Lond) 2017. PMID 28816102
AIM: The efficacy of gadolinium (Gd) chelates as contrast agents for magnetic resonance imaging remains limited owing to poor relaxivity and toxic effects. Here, the effect of the hydration of the hydrogel structure on the relaxometric properties of Gd-DTPA is explained for the first time and called Hydrodenticity. ...
AIM: The efficacy of gadolinium (Gd) chelates as contrast agents for magnetic resonance imaging remains limited owing to poor relaxiv …
Gadolinium-DTPA-dextran: a macromolecular MR blood pool contrast agent.
Sirlin CB, et al. Acad Radiol 2004. PMID 15596374
MATERIALS AND METHODS: [Gd]DTPA-dextran (187 gadolinium atoms per dextran, molecular weight 165 kD, diameter 17.6 nm) was synthesized. ...Coronal 3D MR angiographic sequences were obtained before and at several time points up to 72 hours after the intravenous bolus injection of [Gd]DTPA-dextran providing gadolinium at either 0.05 (n = 4) or 0.1 mmol/kg (n = 8) or [Gd]DTPA-bismethylamide (BMA) providing gadolinium at 0.1 mmol/kg (n = 3). ...
MATERIALS AND METHODS: [Gd]DTPA-dextran (187 gadolinium atoms per dextran, molecular weight 165 kD, diameter 17.6 nm) was synt …
Enhanced conjugation stability and blood circulation time of macromolecular gadolinium-DTPA contrast agent.
Jenjob R, et al. Mater Sci Eng C Mater Biol Appl 2016. PMID 26838894
Chelation stability of Gd-DTPA-Pullulan was estimated, and only 0.2% and 0.00045% of Gd(3+) were released from Gd-DTPA-Pullulan after 2h incubation with Ca(2+) and Fe(2+), respectively. Gd-DTPA-Pullulan displayed the extended plasma half-life (t1/2,α=0.43 h, t1/2,β=2.32 h), much longer than 0.11h and 0.79 h of Gd-EOB-DTPA. ...
Chelation stability of Gd-DTPA-Pullulan was estimated, and only 0.2% and 0.00045% of Gd(3+) were released from Gd-DTPA-Pullula …
Gadoxate disodium: gadolinium EOB DTPA, gadoxetic acid, Gd-EOB-DTPA.
[No authors listed] Drugs R D 2004 - Review. PMID 15230630
Gadoxate disodium [gadolinium EOB DTPA, Gd-EOB-DTPA, gadoxetic acid, Eovist injection, Primovist] is a hydrophilic paramagnetic contrast agent being developed by Schering AG for hepatobiliary magnetic resonance imaging. ...
Gadoxate disodium [gadolinium EOB DTPA, Gd-EOB-DTPA, gadoxetic acid, Eovist injection, Primovist] is a hydrophilic para …
Feasibility of gadoteric acid for delayed gadolinium-enhanced MRI of cartilage (dGEMRIC) at the wrist and knee and comparison with Gd-DTPA.
Rehnitz C, et al. J Magn Reson Imaging 2017. PMID 28263424
PURPOSE: To assess the feasibility of gadoteric acid for delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMRIC) and to compare the dGEMRIC values obtained using gadoteric acid with those obtained by an equimolar dose of Gd-DTPA. ...Similarly, at the knee, there was no significant difference in delta R1 (0.39 ± 0.18 [0.32;0.47]/s for gadoteric acid and 0.41 ± 0.09 [0.38;0.45]/s for Gd-DTPA, P = 0.59) or the relative decrease in T(1) (0.30 ± 0.10 [0.26;0.34] msec for gadoteric acid and 0.33 ± 0.05 [0.30;0.35] msec for Gd-DTPA, P = 0.28). ...
PURPOSE: To assess the feasibility of gadoteric acid for delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMRIC …
Acceleration of natural-abundance solid-state MAS NMR measurements on bone by paramagnetic relaxation from gadolinium-DTPA.
Mroue KH, et al. J Magn Reson 2014. PMID 24881032 Free PMC article.
For over two decades, gadolinium(III)-DTPA (Gd-DTPA, DTPA=Diethylene triamine pentaacetic acid) has been one of the most widely used contrast-enhancement agents in magnetic resonance imaging (MRI). ...These results obtained from (13)C-detected CPMAS experiments were further confirmed using (1)H-detected ultrafast MAS experiments on Gd-DTPA doped bone samples. ...
For over two decades, gadolinium(III)-DTPA (Gd-DTPA, DTPA=Diethylene triamine pentaacetic acid) has been one of …
3,949 results
Jump to page
Feedback